RenovoRx
RNXT | NASDAQ
$0.94
-$0.10 (-9.62%)
At close: Nov 16, 2026, 3:59 PM ET
$0.97
+$0.03 (+3.61%)
After-hours:
Nov 16, 2026, 7:58 PM ET
-9.62%
(1D)No price chart data available for 1D timeframe.
Rating
47.8
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #336/1021 (Top 33%)
Key Statistics
Market Data
Market Cap $45.11M
1D Range
0.90 1.06
52W Range
0.73 2.52
Valuation (TTM)
PE -2.94
PB 4.86
EV/EBITDA -2.77
Valuation (NTM)
Forward PE N/A
Forward PEG 0.60
Price Target $9.00
Cash Flow
FCF Yield -27.1%
SBC Adj. FCF Yield -30.7%
SBC Impact -13.4%
Margins
Gross Margin 84.0%
Operating Margin -483.9%
FCF Margin -440.4%
Growth (CAGR)
Revenue 3Y | 5Y 112.4% |
87.5%
Dil EPS 3Y | 5Y 8.4% |
17.0%
FCF 3Y | 5Y -16.6% |
-5.5%
Returns
ROA -104.7%
ROE -149.0%
ROIC -128.2%
Financial Health
Net Cash
$10.18M
Current Ratio 5.65
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative dru...
Sector Healthcare
Industry Biotechnology
Employees 17
IPO Date Aug 26, 2021
Website renovorx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
-$0.07
Miss -16.67%
YoY:
+12.50% REV
$1.07M
Beat +0.14%
YoY:
+300.75%Next Earnings
Mar 29, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$9.00
Upside
+857.45%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove RNXT